Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002625 · ClinicalTrials.gov registry record · Phase 1
Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00002625: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00002625 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002625, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of topotecan and radiation therapy in treating patients who have solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells.
Interventions
- DRUG topotecan hydrochloride
- RADIATION low-LET electron therapy
- RADIATION low-LET photon therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 1995-03 |
| Est. Completion | 2000-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002625
The ClinicalTrials.gov registry entry for NCT00002625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which topotecan hydrochloride is the first listed.
NCT00002625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002625 about?
NCT00002625 is a clinical study titled "Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma". Phase I trial to study the effectiveness of topotecan and radiation therapy in treating patients who have solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer...
What is the current status of trial NCT00002625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 1995-03. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00002625?
The interventions under investigation include: topotecan hydrochloride (DRUG), low-LET electron therapy (RADIATION), low-LET photon therapy (RADIATION).
Who is sponsoring clinical trial NCT00002625?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.